In 2023, it was estimated that almost 21 percent of those aged 65 years and older in the United States had been diagnosed with diabetes. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had diabetes from 2019 to 2023.

In the period from August 2021 to August 2023, it was estimated that around ** percent of adults in the United States aged 60 years and older had either diagnosed or undiagnosed diabetes. This statistic shows the percentage of adults in the United States with diagnosed or undiagnosed diabetes, by age.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

In 2019, the death rate for diabetes among men in the United States aged 65 years and older was around 150 per 100,000 population, compared to a rate of 96 per 100,000 population among women. This statistic shows the death rates for diabetes among adults in the United States aged 65 years and older from 2000 to 2019, by gender.

Abstract (en): The Research on Early Life and Aging Trends and Effects (RELATE) study compiles cross-national data that contain information that can be used to examine the effects of early life conditions on older adult health conditions, including heart disease, diabetes, obesity, functionality, mortality, and self-reported health. The complete cross sectional/longitudinal dataset (n=147,278) was compiled from major studies of older adults or households across the world that in most instances are representative of the older adult population either nationally, in major urban centers, or in provinces. It includes over 180 variables with information on demographic and geographic variables along with information about early life conditions and life course events for older adults in low, middle and high income countries. Selected variables were harmonized to facilitate cross national comparisons. In this first public release of the RELATE data, a subset of the data (n=88,273) is being released. The subset includes harmonized data of older adults from the following regions of the world: Africa (Ghana and South Africa), Asia (China, India), Latin America (Costa Rica, major cities in Latin America), and the United States (Puerto Rico, Wisconsin). This first release of the data collection is composed of 19 downloadable parts: Part 1 includes the harmonized cross-national RELATE dataset, which harmonizes data from parts 2 through 19. Specifically, parts 2 through 19 include data from Costa Rica (Part 2), Puerto Rico (Part 3), the United States (Wisconsin) (Part 4), Argentina (Part 5), Barbados (Part 6), Brazil (Part 7), Chile (Part 8), Cuba (Part 9), Mexico (Parts 10 and 15), Uruguay (Part 11), China (Parts 12, 18, and 19), Ghana (Part 13), India (Part 14), Russia (Part 16), and South Africa (Part 17). The Health and Retirement Study (HRS) was also used in the compilation of the larger RELATE data set (HRS) (N=12,527), and these data are now available for public release on the HRS data products page. To access the HRS data that are part of the RELATE data set, please see the collection notes below. The purpose of this study was to compile and harmonize cross-national data from both the developing and developed world to allow for the examination of how early life conditions are related to older adult health and well being. The selection of countries for this study was based on their diversity but also on the availability of comprehensive cross sectional/panel survey data for older adults born in the early to mid 20th century in low, middle and high income countries. These data were then utilized to create the harmonized cross-national RELATE data (Part 1). Specifically, data that are being released in this version of the RELATE study come from the following studies: CHNS (China Health and Nutrition Study) CLHLS (Chinese Longitudinal Healthy Longevity Survey) CRELES (Costa Rican Study of Longevity and Healthy Aging) PREHCO (Puerto Rican Elderly: Health Conditions) SABE (Study of Aging Survey on Health and Well Being of Elders) SAGE (WHO Study on Global Ageing and Adult Health) WLS (Wisconsin Longitudinal Study) Note that the countries selected represent a diverse range in national income levels: Barbados and the United States (including Puerto Rico) represent high income countries; Argentina, Cuba, Uruguay, Chile, Costa Rica, Brazil, Mexico, and Russia represent upper middle income countries; China and India represent lower middle income countries; and Ghana represents a low income country. Users should refer to the technical report that accompanies the RELATE data for more detailed information regarding the study design of the surveys used in the construction of the cross-national data. The Research on Early Life and Aging Trends and Effects (RELATE) data includes an array of variables, including basic demographic variables (age, gender, education), variables relating to early life conditions (height, knee height, rural/urban birthplace, childhood health, childhood socioeconomic status), adult socioeconomic status (income, wealth), adult lifestyle (smoking, drinking, exercising, diet), and health outcomes (self-reported health, chronic conditions, difficulty with functionality, obesity, mortality). Not all countries have the same variables. Please refer to the technical report that is part of the documentation for more detail regarding the variables available across countries. Sample weights are applicable to all countries exc...

Stata code for "Diabetes and all-cause mortality among middle-aged and older adults in China, England, Mexico, rural South Africa, and the United States: A population-based study of longitudinal aging cohorts"

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

Abstract

The multi-country Study on Global Ageing and Adult Health (SAGE) is run by the World Health Organization's Multi-Country Studies unit in the Health Systems and Innovation Cluster. SAGE is part of the unit's Longitudinal Study Programme which is compiling longitudinal data on the health and well-being of adult populations, and the ageing process, through primary data collection and secondary data analysis. SAGE baseline data (Wave 0, 2002/3) was collected as part of WHO's World Health Survey http://www.who.int/healthinfo/survey/en/index.html (WHS). SAGE Wave 2 (2014/15) provides a comprehensive data set on the health and well-being of adults in six low and middle-income countries: China, Ghana, India, Mexico, Russian Federation and South Africa.

Objectives: To obtain reliable, valid and comparable health, health-related and well-being data over a range of key domains for adult and older adult populations in nationally representative samples To examine patterns and dynamics of age-related changes in health and well-being using longitudinal follow-up of a cohort as they age, and to investigate socio-economic consequences of these health changes To supplement and cross-validate self-reported measures of health and the anchoring vignette approach to improving comparability of self-reported measures, through measured performance tests for selected health domains To collect health examination and biomarker data that improves reliability of morbidity and risk factor data and to objectively monitor the effect of interventions

Additional Objectives: To generate large cohorts of older adult populations and comparison cohorts of younger populations for following-up intermediate outcomes, monitoring trends, examining transitions and life events, and addressing relationships between determinants and health, well-being and health-related outcomes To develop a mechanism to link survey data to demographic surveillance site data To build linkages with other national and multi-country ageing studies To improve the methodologies to enhance the reliability and validity of health outcomes and determinants data To provide a public-access information base to engage all stakeholders, including national policy makers and health systems planners, in planning and decision-making processes about the health and well-being of older adults

Methods: SAGE's first full round of data collection included both follow-up and new respondents in most participating countries. The goal of the sampling design was to obtain a nationally representative cohort of persons aged 50 years and older, with a smaller cohort of persons aged 18 to 49 for comparison purposes. In the older households, all persons aged 50+ years (for example, spouses and siblings) were invited to participate. Proxy respondents were identified for respondents who were unable to respond for themselves. Standardized SAGE survey instruments were used in all countries consisting of five main parts: 1) household questionnaire; 2) individual questionnaire; 3) proxy questionnaire; 4) verbal autopsy questionnaire; and, 5) appendices including showcards. A VAQ was completed for deaths in the household over the last 24 months. The procedures for including country-specific adaptations to the standardized questionnaire and translations into local languages from English follow those developed by and used for the World Health Survey.

Content: - Household questionnaire 0000 Coversheet 0100 Sampling Information 0200 Geocoding and GPS Information 0300 Recontact Information 0350 Contact Record 0400 Household Roster 0450 Kish Tables and Household Consent 0500 Housing 0600 Household and Family Support Networks and Transfers 0700 Assets and Household Income 0800 Household Expenditures 0900 Interviewer Observations

• Verbal Autopsy questionnaire Section 1: Information on the Deceased and Date/Place of Death Section 1A7: Vital Registration and Certification Section 2: Information on the Respondent Section 3A: Medical History Associated with Final Illness Section 3B: General Signs and Symptoms Associated with Final Illness Section 3E: History of Injuries/Accidents Section 3G: Health Service Utilization Section 4: Background Section 5A: Interviewer Observations

• Individual questionnaire 1000 Socio-Demographic Characteristics 1500 Work History and Benefits 2000 Health State Descriptions 2500 Anthropometrics, Performance Tests and Biomarkers 3000 Risk Factors and Preventive Health Behaviours 4000 Chronic Conditions and Health Services Coverage 5000 Health Care Utilisation 6000 Social Networks 7000 Subjective Well-Being and Quality of Life (WHOQoL-8 and Day Reconstruction Method) 8000 Impact of Caregiving 9000 Interviewer Assessment

• Proxy Questionnaire Section1 Respondent Characteristics and IQ CODE Section2 Health State Descriptions Section4 Chronic Conditions and Health Services Coverage Section5 Health Care Utilisation

Geographic coverage

National coverage

Analysis unit

households and individuals

Universe

The household section of the survey covered all households in 31 of the 32 federal states in Mexico. Colima was excluded. Institutionalised populations are excluded. The individual section covered all persons aged 18 years and older residing within individual households. As the focus of SAGE is older adults, a much larger sample of respondents aged 50 years and older was selected with a smaller comparative sample of respondents aged 18-49 years.

Kind of data

Sample survey data [ssd]

Sampling procedure

In Mexico strata were defined by locality (metropolitan, urban, rural). All 211 PSUs selected for wave 1 were included in the wave 2 sample. A sub-sample of 211 PSUs was selected from the 797 WHS PSUs for the wave 1 sample. The Basic Geo-Statistical Areas (AGEB) defined by the National Institute of Statistics (INEGI) constitutes a PSU. PSUs were selected probability proportional to three factors: a) (WHS/SAGE Wave 0 50plus): number of WHS/SAGE Wave 0 50-plus interviewed at the PSU, b) (State Population): population of the state to which the PSU belongs, c) (WHS/SAGE Wave 0 PSU at county): number of PSUs selected from the county to which the PSU belongs for the WHS/SAGE Wave 0 The first and third factors were included to reduce geographic dispersion. Factor two affords states with larger populations a greater chance of selection.

All WHS/SAGE Wave 0 individuals aged 50 years or older in the selected rural or urban PSUs and a random sample 90% of individuals aged 50 years or older in metropolitan PSUs who had been interviewed for the WHS/SAGE Wave 0 were included in the SAGE Wave 1 ''primary'' sample. The remaining 10% of WHS/SAGE Wave 0 individuals aged 50 years or older in metropolitan areas were then allocated as a ''replacement'' sample for individuals who could not be contacted or did not consent to participate in SAGE Wave 1. A systematic sample of 1000 WHS/SAGE Wave 0 individuals aged 18-49 across all selected PSUs was selected as the ''primary'' sample and 500 as a ''replacement'' sample.

This selection process resulted in a sample which had an over-representation of individuals from metropolitan strata; therefore, it was decided to increase the number of individuals aged 50 years or older from rural and urban strata. This was achieved by including individuals who had not been part of WHS/SAGE Wave 0 (which became a ''supplementary'' sample), although the household in which they lived included an individual from WHS/SAGE Wave 0. All individuals aged 50 or over were included from rural and urban ''18-49 households'' (that is, where an individual aged 18-49 was included in WHS/SAGE Wave 0) as part of the ''primary supplementary'' sample. A systematic random sample of individuals aged 50 years or older was then obtained from urban and rural households where an individual had already been selected as part of the 50 years and older or 18-49 samples. These individuals then formed part of the ''primary supplementary'' sample and the remainder (that is, those not systematically selected) were allocated to the ''replacement supplementary'' sample. Thus, all individuals aged 50 years or older who lived in households in urban and rural PSUs obtained for SAGE Wave 1 were selected as either a primary or replacement participant. A final ''replacement'' sample for the 50 and over age group was obtained from a systematic sample of all individuals aged 50 or over from households which included the individuals already selected for either the 50 and over or 18-49. This sampling strategy also provided participants who had not been included in WHS/SAGE Wave 0, but lived in a household where an individual had been part of WHS/SAGE Wave 0 (that is, the ''supplementary'' sample), in addition to follow-up of individuals who had been included in the WHS/SAGE Wave 0 sample.

Strata: Locality = 3 PSU: AGEBs = 211 SSU: Households = 6549 surveyed TSU: Individual = 6342 surveyed

Mode of data collection

Face-to-face [f2f], CAPI

Research instrument

The questionnaires were based on the SAGE Wave 1 Questionnaires with some modification and new additions, except for verbal autopsy. SAGE Wave 2 used the 2012 version of the WHO Verbal Autopsy Questionnare. SAGE Wave 1 used an adapted version of the Sample Vital Registration iwth Verbal Autopsy (SAVVY) questionnaire. A Household questionnaire was administered to all households eligible for the study. A Verbal Autopsy questionnaire was administered to 50 plus households only. In follow-up 50 plus household if the death occured since the last wave of the study and in a new 50 plus household if the death occurred in the

A dataset of a longitudinal study of over 3,000 Mexican-Americans aged 65 or over living in five southwestern states. The objective is to describe the physical and mental health of the study group and link them to key social variables (e.g., social support, health behavior, acculturation, migration). To the extent possible, the study was modeled after the existing EPESE studies, especially the Duke EPESE, which included a large sample if African-Americans. Unlike the other EPESE studies that were restricted to small geographic areas, the Hispanic EPESE aimed at obtaining a representative sample of community-dwelling Mexican-American elderly residing in Texas, New Mexico, Arizona, Colorado, and California. Approximately 85% of Mexican-American elderly reside in these states and data were obtained that are generalizable to roughly 500,000 older people. The final sample of 3,050 subjects at baseline is comparable to those of the other EPESE studies. Data Availability: Waves I to IV are available through the National Archive of Computerized Data on Aging (NACDA), ICPSR. Also available through NACDA is the ����??Resource Book of the Hispanic Established Populations for the Epidemiologic Studies of the Elderly����?? which offers a thorough review of the data and its applications. All subjects aged 75 or older were interviewed for Wave V and 902 new subjects were added. Hemoglobin A1c test kits were provided to subjects who self-reported diabetes. Approximately 270 of the kits were returned for analyses. Wave V data are being validated and reviewed. A tentative timeline for the archiving of Wave V data is November 2006. Wave VI interviewing and data collection is scheduled to begin in Fall 2006. * Dates of Study: 1993-2006 * Study Features: Longitudinal, Minority oversamples, Anthropometric Measures * Sample Size: ** 1993-4: 3,050 (Wave I) ** 1995-6: 2,438 (Wave II) ** 1998-9: 1,980 (Wave III) ** 2000-1: 1,682 (Wave IV) ** 2004-5: 2,073 (Wave V) ** 2006-7: (Wave VI) Links: * ICPSR Wave 1: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/2851 * ICPSR Wave 2: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/3385 * ICPSR Wave 3: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/4102 * ICPSR Wave 4: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/4314 * ICPSR Wave 5: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/25041 * ICPSR Wave 6: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/29654

The United States self-monitoring blood glucose (SMBG) market, valued at $7.62 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising adoption of advanced SMBG devices. The market's Compound Annual Growth Rate (CAGR) of 6.40% from 2019 to 2024 indicates a steady expansion, which is expected to continue through 2033. Key growth drivers include the increasing diabetic population, particularly among older adults, the rising awareness about diabetes management, and technological advancements leading to more accurate, user-friendly, and convenient glucose monitoring devices. The market is segmented into glucometer devices, test strips, and lancets, with glucometer devices likely representing the largest segment due to the technological innovations leading to smaller, more sophisticated devices and integration with mobile apps for data tracking and management. Furthermore, the growing demand for continuous glucose monitoring (CGM) systems, though not explicitly stated in the provided data, is a significant emerging trend that is likely contributing to market expansion. While challenges exist, such as the high cost of treatment and the potential for inaccuracies with some devices, the market's overall trajectory remains positive due to the sustained need for effective diabetes management. The competitive landscape is characterized by established players like Abbott Diabetes Care, Roche Holding AG, and LifeScan, who hold significant market share. These companies are engaged in continuous innovation to maintain their market dominance by developing technologically advanced devices and expanding their global reach. Smaller companies contribute significantly to innovation and competition, particularly in the development of less expensive and more accessible devices. However, the market's success is closely tied to the broader healthcare landscape, including government regulations, insurance coverage policies, and public health initiatives aimed at diabetes prevention and management. Further research is required to fully quantify the impact of these factors on specific market segments and individual companies within the US SMBG market. Recent developments include: January, 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 20, 2022: Roche announced the launch of the COBAS pulse system in selected countries accepting the CE mark. The COBAS pulse system marks Roche Diagnostics' newest generation of connected point-of-care solutions for professional blood glucose management. The COBAS pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities like those of a smartphone. Following first commercial availability under the CE mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the Cobas Pulse System in other global markets.. Notable trends are: Rising Diabetes Prevalence in the United States.

The Chinese Longitudinal Healthy Longevity Survey (CLHLS) provides information on health status and quality of life of the elderly aged 65 and older in 22 provinces of China in the period 1998 to 2014. The study was conducted to shed light on the determinants of healthy human longevity and oldest-old mortality. To this end, data were collected on a large percent of the oldest population, including centenarian and nonagenarian; the CLHLS provides information on the health, socioeconomic characteristics, family, lifestyle, and demographic profile of this aged population. Data are provided on respondents' health conditions, daily functioning, self-perceptions of health status and quality of life, life satisfaction, mental attitude, and feelings about aging. Respondents were asked about their diet and nutrition, use of medical services, and drinking and smoking habits, including how long ago they quit either or both. They were also asked about their physical activities, reading habits, television viewing, and religious activities, and were tested for motor skills, memory, and visual functioning. In order to ascertain their current state of health, respondents were asked if they suffered from such health conditions as hypertension, diabetes, heart disease, stroke, cancer, emphysema, asthma, tuberculosis, cataracts, glaucoma, gastric or duodenal ulcer, arthritis, Parkinson's disease, bedsores, or other chronic diseases. Respondents were further queried about assistance with bathing, dressing, toileting, or feeding, and who provided help in times of illness. Other questions focused on siblings, parents, and children, the frequency of family visits, and the distance lived from each other. Demographic and background variables include age, sex, ethnicity, place of birth, marital history and status, history of childbirth, living arrangements, education, main occupation before age 60, and sources of financial support.

In 2014, 18.5 percent of adults aged 75 years and older in the United States had diagnosed diabetes. By 2060, prevalence of diabetes in adults aged 75 years and older is projected to be 36 percent. This statistic shows the projected prevalence of diagnosed diabetes in adults in the U.S. by age group for selected years from 2014 to 2060.

The National Health and Nutrition Examination Surveys (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The NHANES combines personal interviews and physical examinations, which focus on different population groups or health topics. These surveys have been conducted by the National Center for Health Statistics (NCHS) on a periodic basis from 1971 to 1994. In 1999 the NHANES became a continuous program with a changing focus on a variety of health and nutrition measurements which were designed to meet current and emerging concerns. The surveys examine a nationally representative sample of approximately 5,000 persons each year. These persons are located in counties across the United States, 15 of which are visited each year. The 2001-2002 NHANES contains data for 11,039 individuals (and MEC examined sample size of 10,477) of all ages. Many questions that were asked in NHANES II, 1976-1980, Hispanic HANES 1982-1984, and NHANES III, 1988-1994, were combined with new questions in the NHANES 2001-2002. As in past health examination surveys, data were collected on the prevalence of chronic conditions in the population. Estimates for previously undiagnosed conditions, as well as those known to and reported by survey respondents, are produced through the survey. Risk factors, those aspects of a person's lifestyle, constitution, heredity, or environment that may increase the chances of developing a certain disease or condition, were examined. Data on smoking, alcohol consumption, sexual practices, drug use, physical fitness and activity, weight, and dietary intake were collected. Information on certain aspects of reproductive health, such as use of oral contraceptives and breastfeeding practices, were also collected. The diseases, medical conditions, and health indicators that were studied include: anemia, cardiovascular disease, diabetes and lower extremity disease, environmental exposures, equilibrium, hearing loss, infectious diseases and immunization, kidney disease, mental health and cognitive functioning, nutrition, obesity, oral health, osteoporosis, physical fitness and physical functioning, reproductive history and sexual behavior, respiratory disease (asthma, chronic bronchitis, emphysema), sexually transmitted diseases, skin diseases, and vision. The sample for the survey was selected to represent the United States population of all ages. Special emphasis in the 2001-2002 NHANES was on adolescent health and the health of older Americans. To produce reliable statistics for these groups, adolescents aged 15-19 years and persons aged 60 years and older were over-sampled for the survey. African Americans and Mexican Americans were also over-sampled to enable accurate estimates for these groups. Several important areas in adolescent health, including nutrition and fitness and other aspects of growth and development, were addressed. Since the United States has experienced dramatic growth in the number of older people during the twentieth century, the aging population has major implications for health care needs, public policy, and research priorities. NCHS is working with public health agencies to increase the knowledge of the health status of older Americans. NHANES has a primary role in this endeavor. In the examination, all participants visit the physician who takes their pulse or blood pressure. Dietary interviews and body measurements are included for everyone. All but the very young have a blood sample taken and see the dentist. Depending upon the age of the participant, the rest of the examination includes tests and procedures to assess the various aspects of health listed above. Usually, the older the individual, the more extensive the examination. Some persons who are unable to come to the examination center may be given a less extensive examination in their homes. Demographic data file variables are grouped into three broad categories: (1) Status Variables: provide core information on the survey participant. Examples of the core variables include interview status, examination status, and sequence number. (Sequence number is a unique ID assigned to each sample person and is required to match the information on this demographic file to the rest of the NHANES 2001-2002 data). (2) Recoded Demographic Variables: these variables include age (age in months for persons through age 19 years, 11 months; age in years for 1-84 year olds, and a top-coded age group of 85 years of age and older), gender, a race/ethnicity variable, current or highest grade of education completed, (less than high school, high school, and more than high school education), country of birth (United States, Mexico, or other foreign born), Poverty Income Ratio (PIR), income, and a pregnancy status variable (adjudicated from various pregnancy related variables). Some of the groupings were made due to limited sample sizes for the two-year data set. (3) Interview and Examination Sample Weight Variables: sample weights are available for analyzing NHANES 2001-2002 data. For a complete listing of survey contents for all years of the NHANES see the document -- Survey Content -- NHANES 1999-2010.

According to Cognitive Market Research, the Blood Glucose Monitoring Devices Market Size will be USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

North America held largest share of xx% in the year 2024 
Europe held share of xx% in the year 2024 
Asia-Pacific held significant share of xx% in the year 2024 
South America held significant share of xx% in the year 2024
Middle East and Africa held significant share of xx% in the year 2024 

MARKET DYNAMICS: KEY DRIVERS

Rising prevalence of diabetes to surge the demand for blood glucose monitoring devices market

As a result of an increase in the incidence of diabetes globally, demand for blood glucose monitoring systems is rising sharply. The majority of individuals with diabetes, i.e., more than 90%, suffer from type 2 diabetes, which is driven by urbanisation, an ageing population, physical inactivity, and escalating prevalence rates of being overweight or obese. For example, based on national diabetes statistics report, of the U.S. adults aged 18 years and older, 97.6 million adults 18 years or older have prediabetes (38.0% of the all adult U.S. population) in 2021. As the demand for diabetes cases increases, more patients have to monitor their blood sugar levels on a regular basis in order to control their condition well. This increased demand is leading to the market for blood glucose monitoring devices as they are needed for early diagnosis, constant management, and treatment of diabetes. Also, improvements in technology and increased understanding of diabetes treatment have contributed to making the devices more affordable and easy to use, further enhancing their uptake. Healthcare systems across the globe are emphasising prevention and timely intervention, which raises the need for effective glucose monitoring solutions. In summary, the rising population with diabetes is the most important driver accelerating the growth of the blood glucose monitoring devices market. The incidence of diabetes rises with age, and elderly individuals are more likely to develop diabetes or diabetes-associated complications. When the elderly population size expands, so does the number of people at risk for diabetes, resulting in an enhanced need for blood glucose monitoring instruments.

Source: https://idf.org/about-diabetes/diabetes-facts-figures/

https://www.who.int/news/item/13-11-2024-urgent-action-needed-as-global-diabetes-cases-increase-four-fold-over-past-decades

https://www.cdc.gov/diabetes/php/data-research/

Restraints

The high prices of blood glucose monitoring devices are hampering the growth of blood glucose monitoring market.

The exorbitant price of blood glucose monitoring equipment, particularly continuous glucose monitors, is one of the major hurdles being faced by this market, which is otherwise growing steadily. Most individuals with diabetes are unable to purchase these devices because, in addition to a significant amount of money at the point of purchase, they also have recurring costs for replacement transmitters and sensors. This economic strain makes it difficult for people to regularly check their blood sugar levels, which is essential in the management of diabetes. For instance, most diabetes patients, an estimated 31%, have indicated that they do not check their glucose levels frequently because test strips are too costly. Moreover, almost half of the patients, approximately 47%, find glucose testing inconvenient, further deterring regular monitoring. These issues indicate the extent to which cost and convenience factors are constraining greater use of glucose monitoring technology. Confirming this, the American Diabetes Association (ADA) survey of 2,595 individuals with diabetes showed that one in five avoided or delayed taking up a pump or CGM, with half of these instances having a direct connection to high costs. During the pandemic, 15% of users who depend on these devices delayed replenishing their supplies, and 70% of them did so because of financial hardship. Prices show this issue as well, such as one test strip may range from 27 to 56 US cents, whereas sensors for continuous or flash glucose monitoring devices run anywhere from $88 to $107 per sensor. These expenses quickly add up, and it becomes difficult for most patients to be consistent about their use. Overall, the high expense...

Characteristics of participants at pre-baseline (N = 11,374)a,b.

The dataset contains hospitalization counts and rates, statewide and by county, for 10 ambulatory care sensitive conditions plus 4 composite measures. Hospitalizations due to these medical conditions are potentially preventable through access to high-quality outpatient care. The conditions include: diabetes short-term complications; diabetes long-term complications; chronic obstructive pulmonary disease (COPD) or asthma in older adults (age 40 and over); hypertension; heart failure; community-acquired pneumonia; urinary tract infection; uncontrolled diabetes; asthma in younger adults (age 18-39); and lower-extremity amputation among patients with diabetes. The composite measures include overall, acute conditions, chronic conditions, and diabetes (new, 2016). The data provides a good starting point for assessing quality of health services in the community. The data does not measure hospital quality. Note: In 2015, HCAI (formerly OSHPD) only released the first three quarters of data due to a change in the reporting of diagnoses from ICD-9-CM to ICD-10-CM codes, effective October 1, 2015. Due to the significant differences resulting from the code change, the ICD-9-CM data is distinguished from the ICD-10-CM data in the data file beginning in 2016.

Abstract

Purpose: The multi-country Study on Global Ageing and Adult Health (SAGE) is run by the World Health Organization's Multi-Country Studies unit in the Innovation, Information, Evidence and Research Cluster. SAGE is part of the unit's Longitudinal Study Programme which is compiling longitudinal data on the health and well-being of adult populations, and the ageing process, through primary data collection and secondary data analysis. SAGE baseline data (Wave 0, 2002/3) was collected as part of WHO's World Health Survey http://www.who.int/healthinfo/survey/en/index.html (WHS). SAGE Wave 1 (2007/10) provides a comprehensive data set on the health and well-being of adults in six low and middle-income countries: China, Ghana, India, Mexico, Russian Federation and South Africa. Objectives: To obtain reliable, valid and comparable health, health-related and well-being data over a range of key domains for adult and older adult populations in nationally representative samples To examine patterns and dynamics of age-related changes in health and well-being using longitudinal follow-up of a cohort as they age, and to investigate socio-economic consequences of these health changes To supplement and cross-validate self-reported measures of health and the anchoring vignette approach to improving comparability of self-reported measures, through measured performance tests for selected health domains To collect health examination and biomarker data that improves reliability of morbidity and risk factor data and to objectively monitor the effect of interventions

Additional Objectives: To generate large cohorts of older adult populations and comparison cohorts of younger populations for following-up intermediate outcomes, monitoring trends, examining transitions and life events, and addressing relationships between determinants and health, well-being and health-related outcomes To develop a mechanism to link survey data to demographic surveillance site data To build linkages with other national and multi-country ageing studies To improve the methodologies to enhance the reliability and validity of health outcomes and determinants data To provide a public-access information base to engage all stakeholders, including national policy makers and health systems planners, in planning and decision-making processes about the health and well-being of older adults

Methods: SAGE's first full round of data collection included both follow-up and new respondents in most participating countries. The goal of the sampling design was to obtain a nationally representative cohort of persons aged 50 years and older, with a smaller cohort of persons aged 18 to 49 for comparison purposes. In the older households, all persons aged 50+ years (for example, spouses and siblings) were invited to participate. Proxy respondents were identified for respondents who were unable to respond for themselves. Standardized SAGE survey instruments were used in all countries consisting of five main parts: 1) household questionnaire; 2) individual questionnaire; 3) proxy questionnaire; 4) verbal autopsy questionnaire; and, 5) appendices including showcards. A VAQ was completed for deaths in the household over the last 24 months. The procedures for including country-specific adaptations to the standardized questionnaire and translations into local languages from English follow those developed by and used for the World Health Survey.

Content Household questionnaire 0000 Coversheet 0100 Sampling Information 0200 Geocoding and GPS Information 0300 Recontact Information 0350 Contact Record 0400 Household Roster 0450 Kish Tables and Household Consent 0500 Housing 0600 Household and Family Support Networks and Transfers 0700 Assets and Household Income 0800 Household Expenditures 0900 Interviewer Observations

Individual questionnaire 1000 Socio-Demographic Characteristics 1500 Work History and Benefits 2000 Health State Descriptions and Vignettes 2500 Anthropometrics, Performance Tests and Biomarkers 3000 Risk Factors and Preventive Health Behaviours 4000 Chronic Conditions and Health Services Coverage 5000 Health Care Utilization 6000 Social Cohesion 7000 Subjective Well-Being and Quality of Life (WHOQoL-8 and Day Reconstruction Method) 8000 Impact of Caregiving 9000 Interviewer Assessment

Geographic coverage

National coverage

Analysis unit

households and individuals

Universe

The household section of the survey covered all households in 19 of the 28 states in India which covers 96% of the population. Institutionalised populations are excluded. The individual section covered all persons aged 18 years and older residing within individual households.

Kind of data

Sample survey data [ssd]

Sampling procedure

World Health Survey Sampling India has 28 states and seven union territories. 19 of the 28 states were included in the design representing 96% of the population. India used a stratified multistage cluster sample design. Six states were selected in accordance with their geographic location and level of development. Strata were defined by the 6 states:(Assam, Karnataka, Maharashtra, Rajasthan, Uttar Pradesh and West Bengal), and locality (urban or rural). There are 12 strata in total. The 2000 Census demarcation was used as the sampling frame. Two stage and three stage sampling was adopted in rural and urban areas, respectively. In rural areas PSUs(villages) were selected probability proportional to size. The measure of size being the 2001 Census population in the village. SSUs (households) were selected using systematic sampling. TSUs (individuals) were selected using Kish tables. In urban areas, PSUs(city wards) were selected probability proportional to size. SSUs(census enumeration blocks), two were randomly selected from each PSU. TSU (households) were selected using systematic sampling. QSU (individuals) were selected as in rural areas. A sample of 379 EAs was selected as the primary sampling units(PSU).

SAGE Sampling The SAGE sample was pre-determined as all PSUs and households selected for the WHS/SAGE Wave 0 survey were included. Exceptions are three PSUs in Assam which were replaced as they were inaccessible due to flooding. And a further six PSUs were omitted for which the household roster information was not available. In each selected EA, a listing of the households was conducted to classify each household into the following mutually exclusive categories: 1)Households with a WHS/SAGE Wave 0 respondent aged 50-plus: all members aged 50-plus including the WHS/SAGE Wave 0 respondent were eligible for the individual interview. 2)Households with a WHS/SAGE Wave 0 respondent aged 47-49: all members aged 50-plus including the WHS/SAGE Wave 0 respondent aged 47-49 was eligible for the individual interview. 3)Households with a WHS/SAGE Wave 0 female respondent aged 18-46: all females members aged 18-49 including the WHS/SAGE Wave 0 female respondent aged 18-46 were eligible for the individual interview. 4)Households with a WHS/SAGE Wave 0 male respondent aged 18-46: three households were selected using systematic sampling and one male aged 18-49 was eligible for the individual interview. In the households not selected, all members aged 50-plus were eligible for the individual interview.

Stages of selection Strata: State, Locality=12 PSU: EAs=375 surveyed SSU: Households=10424 surveyed TSU: Individual=12198 surveyed

Mode of data collection

Face-to-face [f2f] PAPI

Research instrument

The questionnaires were based on the WHS Model Questionnaire with some modification and many new additions. A household questionnaire was administered to all households eligible for the study. A Verbal Autopsy questionnaire was administered to households that had a death in the last 24 months. An Individual questionniare was administered to eligible respondents identified from the household roster. A Proxy questionnaire was administered to individual respondents who had cognitive limitations. A Womans Questionnaire was administered to all females aged 18-49 years identified from the household roster. The questionnaires were developed in English and were piloted as part of the SAGE pretest in 2005. All documents were translated into Hindi, Assamese, Kanada and Marathi. SAGE generic questionnaires are available as external resources.

Cleaning operations

Data editing took place at a number of stages including: (1) office editing and coding (2) during data entry (3) structural checking of the CSPro files (4) range and consistency secondary edits in Stata

Response rate

Household Response rate=88% Cooperation rate=92%

Individual: Response rate=68% Cooperation rate=92%

North America Insulin Syringe Market size was valued at USD 259 Million in 2024 and is projected to reach USD 290 Million by 2032, growing at a CAGR of 1.7% from 2025 to 2032.

Key Market Drivers:

Increasing Diabetes Prevalence: According to the Centers for Disease Control and Prevention's (CDC) 2022 National Diabetes Statistics Report, more than 37.3 million Americans (or 11.3% of the US population) have diabetes, with roughly 28.7 million diagnosed and 8.5 million undiagnosed. The number of individuals diagnosed with diabetes has more than quadrupled over the previous 20 years, resulting in a significant and rising need for insulin syringes.

Ageing Population Growth: According to the United States Census Bureau, the number of Americans aged 65 and over is expected to reach 77 million in 2034. This age change is especially relevant for the insulin syringe industry, as type 2 diabetes is more common in older persons.

It was estimated that around 30 percent of those aged 80 years and older who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease. Deaths due to COVID-19 are much higher among those with underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.